Trial Profile

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects With Diabetic Kidney Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Tozorakimab (Primary)
Indications Diabetic nephropathies
Focus Therapeutic Use
Acronyms FRONTIER-1
Sponsors AstraZeneca

Most Recent Events

18 Nov 2024 Cardiovascular insights from FRONTIER-1 presented at the American Heart Association Scientific Sessions 2024
28 Jul 2023 According to an AstraZeneca media release, result data of this study will be anticipated in H2 2023.
15 Jun 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com